Abstract
Introduction: Mutations in the JAK2, CALR, and MPL genes have been shown to have prognostic value in essential thrombocythaemia (ET), but no clear association with morphological changes has been reported so far. We investigated the possible correlation between gene mutations and histopathological features in bone marrow (BM) biopsies of patients with ET. Methods: Marrow cellularity, fibrosis, and the number of total and dysmorphic megakaryocytes and clusters of megakaryocytes were compared to gene mutations in 90 cases of ET at diagnosis. Results: The JAK2V617F mutation was found in 58.9%, CALR in 28.9%, and MPL in 4.4% of the cases, and 7.8% were triple-negative. JAK2V617F-mutated ET showed a high BM cellularity, the lowest number of clusters of megakaryocytes and the highest number of dysmorphic megakaryocytes; CALR-mutated ET showed a reduced BM cellularity, many clusters of large megakaryocytes, and very few dysmorphic megakaryocytes; MPL-mutated ET showed the lowest BM cellularity, the highest number of clustered and large megakaryocytes, and the lowest number of dysmorphic megakaryocytes. Triple-negative ET cases had the highest BM cellularity. Conclusions: Distinct morphological patterns were associated with gene mutations in ET, supporting the classification of ET into different subtypes.
References
1.
Thiele
J
, Kvasnicka
HM
, Orazi
A
, Gianelli
U
, Tefferi
A
, Gisslinger
H
, et al Essential thrombocythaemia. In: Swerdlow
SH
, Campo
E
, Harris
NL
, Jaffe
ES
, Pileri
SA
, Stein
H
, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
. Revised 4th edn. Lyon
: IARC Press
; 2017
. pp. 50
–3
.2.
Malcovati
L
, Rumi
E
, Cazzola
M
. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
. Haematologica
. 2014
Nov
;99
(11
):1650
–2
.
[PubMed]
0390-60783.
Rumi
E
, Cazzola
M
. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
. Blood
. 2017
Feb
;129
(6
):680
–92
.
[PubMed]
0006-49714.
Campbell
PJ
, Scott
LM
, Buck
G
, Wheatley
K
, East
CL
, Marsden
JT
, et al; United Kingdom Myeloproliferative Disorders Study Group
; Medical Research Council Adult Leukaemia Working Party
; Australasian Leukaemia and Lymphoma Group
. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
. Lancet
. 2005
Dec
;366
(9501
):1945
–53
.
[PubMed]
0140-67365.
Finazzi
G
, Rambaldi
A
, Guerini
V
, Carobbo
A
, Barbui
T
. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
. Haematologica
. 2007
Jan
;92
(1
):135
–6
.
[PubMed]
0390-60786.
Rumi
E
, Pietra
D
, Ferretti
V
, Klampfl
T
, Harutyunyan
AS
, Milosevic
JD
, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
. Blood
. 2014
Mar
;123
(10
):1544
–51
.
[PubMed]
0006-49717.
Asp
J
, Andréasson
B
, Hansson
U
, Wasslavik
C
, Abelsson
J
, Johansson
P
, et al Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome
. Haematologica
. 2016
Apr
;101
(4
):e129
–32
.
[PubMed]
0390-60788.
Klampfl
T
, Gisslinger
H
, Harutyunyan
AS
, Nivarthi
H
, Rumi
E
, Milosevic
JD
, et al Somatic mutations of calreticulin in myeloproliferative neoplasms
. N Engl J Med
. 2013
Dec
;369
(25
):2379
–90
.
[PubMed]
0028-47939.
Pich
A
, Riera
L
, Beggiato
E
, Nicolino
B
, Godio
L
, Campisi
P
, et al JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia
. J Clin Pathol
. 2012
Oct
;65
(10
):953
–5
.
[PubMed]
0021-974610.
Thiele
J
, Kvasnicka
HM
, Orazi
A
, Gianelli
U
, Barbui
T
, Barosi
G
, et al Primary myelofibrosis. In: Swerdlow
SH
, Campo
E
, Harris
NL
, Jaffe
ES
, Pileri
SA
, Stein
H
, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
. Revised 4th edn. Lyon
: IARC Press
; 2017
. pp. 44
–50
.11.
Vannucchi
AM
, Antonioli
E
, Pancrazzi
A
, Guglielmelli
P
, Di Lollo
S
, Alterini
R
, et al The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W[{GT}]L/K mutation. ASH Annual Meeting Abstracts
. Blood
. 2007
;110
:678
.0006-497112.
Michiels
JJ
, Pich
A
, de Raeve
H
, Camp
V
, Schwarz
J
. WHO Clinical Molecular and Pathological (WHO-CMP) Features of Congenital MPLS505N and the Acquired MPLW515l/K Mutated Essential Thrombocythemia and Myelofibrosis
. J Hematol Thrombo Dis
. 2014
;2
(06
):181
. 13.
Nangalia
J
, Massie
CE
, Baxter
EJ
, Nice
FL
, Gundem
G
, Wedge
DC
, et al Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
. N Engl J Med
. 2013
Dec
;369
(25
):2391
–405
.
[PubMed]
0028-479314.
Rumi
E
, Pietra
D
, Pascutto
C
, Guglielmelli
P
, Martínez-Trillos
A
, Casetti
I
, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
. Blood
. 2014
Aug
;124
(7
):1062
–9
.
[PubMed]
0006-497115.
Angona
A
, Fernández-Rodríguez
C
, Alvarez-Larrán
A
, Camacho
L
, Longarón
R
, Torres
E
, et al Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
. Blood Cancer J
. 2016
Aug
;6
(8
):e463
.
[PubMed]
2044-538516.
Langabeer
SE
, Andrikovics
H
, Asp
J
, Bellosillo
B
, Carillo
S
, Haslam
K
, et al; MPN&MPNr-EuroNet
. Molecular diagnostics of myeloproliferative neoplasms
. Eur J Haematol
. 2015
Oct
;95
(4
):270
–9
.
[PubMed]
0902-444117.
Ju
M
, Fu
R
, Li
H
, Liu
X
, Xue
F
, Chen
Y
, et al Mutation profiling by targeted sequencing of “triple-negative” essential thrombocythaemia patients
. Br J Haematol
. 2018
Jun
;181
(6
):857
–60
.
[PubMed]
0007-104818.
Tefferi
A
, Barbui
T
. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
. Am J Hematol
. 2017
Jan
;92
(1
):94
–108
.
[PubMed]
0361-8609© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
